



FOR IMMEDIATE RELEASE

CONTACT: Jay Riley
(410) 369-1277

ST. JOHN PROPERTIES SIGNS PHARMACEUTICAL COMPANY EISAI INC. TO 40,000 SQUARE FOOT LEASE AT GREENLEIGH AT CROSSROADS

United States subsidiary of Tokyo-based company relocating approximately 55 employees

BALTIMORE, MD (September 13, 2017) – St. John Properties, Inc. has signed Eisai Inc., the United States pharmaceutical subsidiary of Tokyo-based Eisai Co, Ltd., to a 40,000 square foot full-building lease within 11675 Crossroads Circle. The flex/R&D building was built on a speculative basis, and is located within Greenleigh at Crossroads, a 550-acre mixed-use community in the White Marsh area of Baltimore County. The company plans to relocate approximately 55 employees from its existing location in Baltimore City in 2019, after construction at the site is completed. Matt Lenihan of St. John Properties represented the landlord in this transaction.

Eisai Inc. is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. The U.S. headquarters, commercial and clinical development organizations are located in New Jersey; discovery labs are in Massachusetts and Pennsylvania; and the global demand chain organization resides in Maryland and North Carolina. The Greenleigh at Crossroads facility will be used to manufacture and distribute Gliadel[®], a product used to treat brain cancer.

“This new Baltimore location enables Eisai a seamless transition in its efforts to continue to produce Gliadel[®] for thousands of patients worldwide,” said Shaji Procida, President and Chief Operating Officer of Eisai Inc. “It also demonstrates our commitment to constantly improve our services in areas of unmet need and to remain nimble to adapt to our changing business environment, while executing on our [human health care \(hhc\) mission](#) of giving our first thought to patients and their families, and helping to increase the benefits health care provides.”

St. John Properties, together with Somerset Construction Company and Elm Street Development, are currently engaged in the construction of Greenleigh at Crossroads, utilizing a concept plan that consists of 1,000 single-family homes and townhomes, 500 multi-family units, three mid-rise Class “A” commercial office buildings containing approximately 300,000 square feet of space; 443,000 square feet of single-story office space; 827,000 square feet of flex/R&D space; 188,000 square feet of retail amenities; and a 120-room SpringHill Suites by Marriott.

Located along MD Route 43 (White Marsh Blvd.) near Interstate 95, Baltimore Crossroads is configured to support more than 2.5 million square feet of commercial office, flex/R&D, warehouse, industrial and retail space, in addition to the hotel and residential components. Approximately 2,500 employees currently live and work in the community, including multi-family residents at the Arbors at Baltimore Crossroads and more than 10,000 jobs are expected to be created upon the completion of Baltimore Crossroads.

“This represents a tremendous win for Greenleigh at Crossroads given the influx of high-paying jobs destined to support our retail tenants and restaurants, as well as opening the possibility for the purchase or rental of residential properties within the community,” explained Richard Williamson, Senior Vice President of Leasing and Marketing for St. John Properties. “Attracting strong economic generators to Baltimore County was an extremely high priority in the design and planning of the community. This usage highlights the many advantages of Greenleigh at Crossroads including its amenities, ability to handle corporate growth and access to transportation infrastructure. With available product on-hand, we are able to immediately respond to the diversified real estate requirements of end-users, including the expansion needs of current and future tenants.”

“Based on the unique skill set of our talented employees and our strong ties to the local community, remaining in Baltimore is a priority for Eisai,” said Trudy Burke, President, Oncology Demand Chain Unit, and Baltimore Site Head. “The new site will provide a right-sized physical environment for our employees, which will help streamline operations and foster a culture of growth and innovation.”

“Our economic strength is due, in large part, to keeping innovation companies such as Eisai here in our business community. We’ve created a successful business climate that is bringing approximately 55 new life sciences jobs to Baltimore County. Eisai’s commitment to staying in the region is based on Baltimore’s powerhouse combination of well-educated workers, world-renowned medical researchers and well-located business communities. There’s a strategic advantage when you have available space for

companies as they grow. Baltimore Crossroads offers the business environment Eisai needs,” said Baltimore County Executive Kevin Kamenetz.

About St. St. John Properties, Inc.

St. John Properties, Inc., founded in 1971, owns and has developed more than 18 million square feet of flex/R&D, office, retail and warehouse space in Maryland, Colorado, Louisiana, Nevada, Pennsylvania, Virginia, Utah and Wisconsin. For more information about the company, visit <http://www.sjpi.com>.

For media inquiries, contact:
Larry Lichtenauer, Lawrence Howard & Associates, Inc.
410-363-6205

About Eisai Inc.

At Eisai Inc., *human health care (hhc)* is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

For media inquiries, contact:
Patricia Councill, Eisai Inc.
201-746-2139